Comparison · NCT01205776-69a97aa3
Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With Complete Revascularization (Residual = 0)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Percutaneous Coronary Intervention (PCI) vs Coronary Artery Bypass Graft (CABG): Number of Participants With Complete Revascularization (Residual = 0). Trial comparisons, record NCT01205776-69a97aa3. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01205776-69a97aa3
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.282 | 0.254 | 0.312 | wilson | |
| Risk in group 2 | 0.476 | 0.283 | 0.676 | wilson | |
| Risk difference, group 1 minus group 2 | -0.194 | -0.396 | 0.00132 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.593 | 0.374 | 0.94 | log | |
| Odds ratio, group 1 over group 2 | 0.433 | 0.182 | 1.03 | log | |
| Number needed to treat, for one fewer participant with the outcome on Percutaneous Coronary Intervention (PCI) than on Coronary Artery Bypass Graft (CABG) | 5.16 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Percutaneous Coronary Intervention (PCI) | Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS | 259 | 917 | OG000 |
| Group 2 | Coronary Artery Bypass Graft (CABG) | Those patients receiving Coronary Artery Bypass Graft (CABG) | 10 | 21 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Complete Revascularization (Residual = 0)
- Description
1. Complete anatomic revascularization requires revascularization of all vessels ≥2.0 mm reference vessel diameter with a DS ≥60% (both as measured by core angiographic laboratory analysis).~ -While this will be the pre-specified criteria for anatomically significant lesions, sensitivity analysis will be performed using different criteria (e.g. ≥2.5 mm vessels, DS ≥70%, etc.)~2. From the baseline angiogram, the angiographic core lab will identify and designate those lesions and vessels requiring revascularization in all subjects according to this definition, prior to knowledge of the extent of actual revascularization.~3. Following PCI, the angiographic core lab will determine the extent of revascularization (vessels with TIMI 2or3 flow post procedure with a core laboratory DS \<50% considered successfully revascularized).~4. Following CABG, the angiographic core lab will determine the extent of revascularization or if there is a repeat angiogram during the index hospitalization.
- Time frame
- At Baseline
- Population
- Not all PCI patients have Baseline and Post-PCI Syntax score assessment.
Source ClinicalTrials.gov
Trial
- Title
- EXCEL Clinical Trial
- NCT number
- NCT01205776
- Phases
- NA
- Conditions
Chronic Coronary Occlusion, Unprotected Left Main Coronary Artery Disease, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Interventions
- Percutaneous Coronary Intervention, CABG
- Lead sponsor
- Abbott Medical Devices
- Results first posted
- 2018-03-29
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01205776?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01205776-69a97aa3